产品名称
Factor V human, aqueous glycerol solution, ≥25 units/mg protein
biological source
human
form
aqueous glycerol solution
specific activity
≥25 units/mg protein
technique(s)
ligand binding assay: suitable
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Quality Level
Gene Information
human ... F5(2153)
Application
Factor V is a key component in blood coagulation systems, where deficiencies can inhibit thrombin generation and affect hemostasis. It has been used in studies of Coagulopathic bleeding which occurs following injury and is a leading cause of in hospital deaths.
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
General description
Factor V is a single chain glycoprotein involved in the blood coagulation cascade. It is the procofactor of Va which accelerates the conversion of prothrombin to thrombin.
Other Notes
One unit is equivalent to the Factor V activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
View this factors role in the Coagulation Cascade.
Physical form
Aqueous solution containing 50% (v/v) glycerol
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
高风险级别生物产品--人源产品
此项目有
Early coagulopathy in trauma patients: An on-scene and hospital admission study.
Floccard B., et al.
Injury (2010)
Eliza A Ruben et al.
Blood, 137(22), 3137-3144 (2021-03-09)
Coagulation factor V (fV) is the precursor of fVa, which, together with fXa, Ca2+, and phospholipids, defines the prothrombinase complex and activates prothrombin in the penultimate step of the coagulation cascade. We solved the cryogenic electron microscopy (cryo-EM) structures of
Sandro B Rizoli et al.
The Journal of trauma, 71(5 Suppl 1), S427-S434 (2011-12-17)
Coagulopathic bleeding is a leading cause of in-hospital death after injury. A recently proposed transfusion strategy calls for early and aggressive frozen plasma transfusion to bleeding trauma patients, thus addressing trauma-associated coagulopathy (TAC) by transfusing clotting factors (CFs). This strategy
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持